BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29962332)

  • 1. Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers.
    Cho KS; Hong SJ; Ahn MH; Pal S; Choung PH; Sangshetti J; Arote RB
    Curr Pharm Des; 2018; 24(16):1788-1800. PubMed ID: 29962332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
    Revia RA; Stephen ZR; Zhang M
    Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
    Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
    Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
    Zhao J; Feng SS
    Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
    Subhan MA; Torchilin VP
    Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery.
    He C; Yue H; Xu L; Liu Y; Song Y; Tang C; Yin C
    Acta Biomater; 2020 Feb; 103():213-222. PubMed ID: 31812844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
    Gandhi NS; Tekade RK; Chougule MB
    J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic Delivery.
    Xu C; Li D; Cao Z; Xiong M; Yang X; Wang J
    Nano Lett; 2019 Apr; 19(4):2688-2693. PubMed ID: 30844291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation.
    Fernandes F; Kotharkar P; Chakravorty A; Kowshik M; Talukdar I
    Curr Stem Cell Res Ther; 2020; 15(2):155-172. PubMed ID: 31789134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
    Babu A; Munshi A; Ramesh R
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SiRNA drug delivery by biodegradable polymeric nanoparticles.
    Yuan X; Li L; Rathinavelu A; Hao J; Narasimhan M; He M; Heitlage V; Tam L; Viqar S; Salehi M
    J Nanosci Nanotechnol; 2006; 6(9-10):2821-8. PubMed ID: 17048488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
    Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
    Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.
    Li J; Wang Y; Xue S; Sun J; Zhang W; Hu P; Ji L; Mao Z
    Int J Nanomedicine; 2016; 11():4609-4624. PubMed ID: 27695321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.